No Picture
News

Helix Receives Expanded Emergency Use Authorization for On-site Unsupervised Self-Collection and Asymptomatic Screening with the Helix® COVID-19 Test

As one of the few tests with these indications, the Helix® COVID-19 Test provides organizations with significantly more flexibility in how they operate testing sites to support broad back-to-work and school screening

SAN MATEO, Calif., Oct. 26, 2020… […]

No Picture
News

Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020

Conference Call Scheduled for Wednesday, October 28 at 4:30 p.m. Eastern Time

SAN DIEGO, Oct. 21, 2020 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel… […]

No Picture
News

Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

Partnership Leverages TScan’s Proprietary High-throughput TCR/Target Discovery Platform and Poseida’s Proprietary Allogeneic T Cell Approach to Advance Potential TCR-T Treatments

SAN DIEGO and WALTHAM, Mass., Oct. 21, 2020 /PRNewswire/ — Poseida The… […]

No Picture
News

Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study

– Adaptive Clinical Trial Platform in Glioblastoma Multiforme — Expected to serve as basis for VAL-083’s new drug application (NDA) submission and registration- Expansion of clinical site involvement with 31 U.S. sites actively enrolling patients; i… […]

No Picture
News

Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions

– Randomized, placebo controlled, clinical trial is being conducted at University of Kansas Medical Center, Kansas City, Kansas- Enrolling highly symptomatic participants within 28 days of injury- First in class investigational drug to potentially t… […]

No Picture
News

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance

— Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating init… […]

No Picture
News

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]